Dovitinib lactate, with the CAS number 915769-50-5, is a chemical compound that serves as a lactate salt of dovitinib, a potent inhibitor of multiple receptor tyrosine kinases, including VEGFR, PDGFR, and FGFR. This compound is primarily investigated for its potential therapeutic applications in oncology, particularly in the treatment of various cancers by inhibiting tumor growth and angiogenesis. Dovitinib lactate is characterized by its ability to interfere with signaling pathways that promote cancer cell proliferation and survival. The lactate form enhances its solubility and bioavailability, making it more suitable for pharmaceutical formulations. In terms of physical properties, it typically appears as a white to off-white solid, and its stability and solubility can vary depending on the formulation and environmental conditions. As with many pharmaceutical compounds, safety and efficacy are evaluated through clinical trials, and its use is subject to regulatory approval. Overall, dovitinib lactate represents a significant area of research in targeted cancer therapies.

Dovitinib lactate

915769-50-5: 4-Amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone 2-hydroxypropanoate hydrate (1:1:1), 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one

Dovitinib lactate hydrate

Receptor tyrosine kinase inhibitor; anti-angiogenesis; anti-oncogenesis

Dovitinib Lactate

4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate hydrate

Dovitinib lactate hydrate (TKI258) is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit).

CAS 915769-50-5: Dovitinib lactate

Dovitinib lactate hydrate

Ref: 54-BUP10685

Dovitinib Lactate

Ref: 3D-FD65011

4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate hydrate

Ref: IN-DA006TI0

Dovitinib lactate hydrate

Ref: TM-T6479